Commercial, IP & Psychoactive Medicines Team
Harry sits across the Corporate and Commercial and Psychoactive Medicines Law teams. He advises primarily on commercial matters, including protecting intellectual property, with a focus on trade marks.
He also has a specialist interest in the psychoactive medicines and cannabis sectors, providing advice on regulatory and commercial matters.
Examples of the types of matter he works on include:
• Managing international trade mark portfolios
• Carrying out pre-application searches and applications for UK and EU trade marks
• Managing opposition and cancellation proceedings for both applicants and respondents in trade mark disputes
• Negotiating settlements in trade mark disputes, both national and international
• Other general intellectual property advice
• Investments into early stage companies
• Negotiating sponsorship agreements and other commercial contracts
• Drafting commercial terms and conditions and related documents
• General company law matters
• Regulatory advice in relation to the set-up and administration of medicinal cannabis import/export, growth, distribution and clinic businesses, and related matters
• Regulatory advice in relation to the status of psychedelic and other controlled drugs for commercial and research purposes, and related matters
His previous experience in market-leading firms such as Freshfields Bruckhaus Deringer means that he is used to dealing with the most complex and demanding mandates. Alongside his commercial and intellectual property work, Harry decided to focus on the legal space around plant and psychoactive medicines because of his desire to help clients at the forefront of tackling the modern mental health epidemic. Clients value his personable manner and practical, commercial advice.
Outside of his work as a solicitor, Harry volunteers with a number of harm reduction and evidence-based drugs reform organisations, including the PAR campaign, PsyCare UK and Breaking Convention.